Financial News

Novo Nordisk FY24 Results

Diabetes and Obesity care increased by 26%, driven by GLP-1 diabetes sales growth of 21% and Obesity care growing by 56%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Image: Novo Nordisk

Novo Nordisk FY Revenues: $40.6 billion (+25%) FY Earnings: $14.1 billion (+21%) Comments: Sales in North America Operations increased by 30% in Danish kroner. Sales in International Operations increased by 17% in Danish kroner. Sales within Diabetes and Obesity care increased by 26% in Danish kroner to DKK 271.8 billion, mainly driven by GLP-1 diabetes sales growth of 21% in Danish kroner and Obesity care growing by 56% in Danish kroner to DKK 65.1 billion. Rare disease sales increa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters